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Anaphylaxis is a type I hypersensitivity reaction that is potentially fatal if not promptly
treated. It is a clinical diagnosis, although measurement of serial serum total mast
cell tryptase (MCT) is gold standard and may help differentiate anaphylaxis from its
mimics. The performance characteristics of MCT assays in anaphylaxis has been variable
in previous studies, due to multiple factors including differences in the definition of
anaphylaxis, methods of MCT interpretation, clinical setting of anaphylaxis, causative
agents, and timing of blood sample. An international consensus equation for MCT to
interpret mast cell activation has been proposed and recently validated in the context
of peri-operative anaphylaxis during general anesthesia. There has been an interest
in the detection of newer biomarkers in anaphylaxis including platelet activation factor
(PAF), chymase, carboxypeptidase A3, dipeptidyl peptidase I (DPPI), basogranulin, and
CCL-2. The key determinants of an ideal biomarker in anaphylaxis are half-life, sample
handling and processing requirements, and cost. There may be a role for metabolomics
and systems biology in the exploration of novel biomarkers in anaphylaxis. Future
studies applying these approaches might provide greater insight into factors determining
severity, clinical risk stratification, identification of mast cell disorders and improving our
understanding of this relatively complex acute immunological condition. Post mortem
MCT evaluation is used in Forensic Medicine during autopsy for cases involving sudden
death or suspected anaphylaxis. Interpretation of post mortem MCT is challenging since
there is limited published evidence and the test is confounded by multiple variables
largely linked to putrefaction and site of sampling. Thus, there is no international
consensus on a reference range. In this state of the art review, we will focus on the
practical challenges in the laboratory diagnosis of anaphylaxis and critically appraise (a)
performance characteristics of MCT in anaphylaxis in different clinical scenarios (b) the
role for novel biomarkers and (c) post mortem MCT and its role in fatal anaphylaxis.
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INTRODUCTION
Anaphylaxis is a systemic hypersensitivity reaction usually
involving two or more organs including skin/mucus membranes,
airways, cardiovascular, and/or gastrointestinal systems. It
remains a clinical diagnosis and the World Allergy Organization
(WAO) published diagnostic criteria based on clinical parameters
(1, 2). The current gold standard laboratory test involves
measurement of serum total tryptase during an acute phase
followed by a baseline measurement (≥24 h) (1, 2). Whilst a rise
in serum total mast cell tryptase (MCT) is diagnostic, this is not
seen in all cases of anaphylaxis.
Serial MCT measurements are a useful adjunct during
elective specialist assessment for investigation and long-term
management of anaphylaxis. It is particularly useful in patients
where there may be a paucity of historical information relating to
the index episode, to differentiate anaphylaxis from its mimics or
in patients with an incomplete clinical history.
As well as reviewing the basic concepts of MCT measurement
and its interpretation, this article will critically appraise the
published literature regarding clinical utility and performance of
MCT in anaphylaxis occurring both in and outside the hospital.
This article also focuses on measurement of MCT in serum
obtained at post-mortem in suspected fatal anaphylaxis and
explores the role for new candidate biomarkers.
ANALYTICAL ASPECTS OF MAST CELL
TRYPTASE MEASUREMENT
Tryptase, a neutral serine protease, is released from secretory
granules of mast cells (3–6). It exists in 2 isoforms, alpha and beta,
encoded by separate genes and is secreted as inactive proenzymes
from resting mast cells: alpha-protryptase and beta-protryptase
(3–6). In contrast to alpha protryptase, beta protryptase is stored
in its mature form in mast cell granules and released following
mast cell degranulation as a teramer bound to heparin and
chondroitin sulfate (3–6). Hence, the totalMCTmeasured during
anaphylaxis is predominantly of the beta tryptase isoform.
PLATFORM FOR TRYPTASE ASSAYS
Globally there is only one manufacturer of MCT assays in the
routine diagnostic setting. External quality assurance (EQA)
schemes are used by laboratories as an assessment of accuracy.
The only manufacturer of in vitro measurement of MCT
represented in the UK based EQA scheme (UKNEQAS), is
Thermo Fisher Scientific. The assay is available on a number
of Thermo Fisher platforms, but all use the same methodology
and reagents to measure total MCT (α and β isoforms). MCT
is detected in serum using ImmunoCAP technology based on
the principle of sandwich immunoassay. Anti-tryptase antibodies
are covalently bound, to a cellulose derivative enclosed in a solid
phase capsule. MCT present in serum will bind to the anti-
tryptase in the solid phase. After a wash step to remove excess
serum and unbound proteins, an enzyme-labeled secondary anti-
tryptase antibody is added, once bound, will contain tryptase in
a sandwich complex. After excess secondary antibody is washed
off, the reaction is stopped. This chemical reaction causes a
color change, fluorescence of which is measured and is directly
proportional to the concentration of MCT in the serum sample.
PERFORMANCE CHARACTERISTICS
Analytical Performance
The manufacturer quoted assay imprecision, determined by inter
and intra assay coefficient of variation (CV), across the full
dynamic range of the assay, is consistent with that expected
for the methodology (inter-assay CV ≤7% and intra-assay CV
≤4%) (7). This is supported by UK EQA data, where the
overall CV for results per distribution (of >200 participants)
consistently achieves a CV of <9.5% with an average CV of
7.3% over the last 6 distributions [personal communication; data
only available to registered users of the UKNEQAS Tryptase
scheme; https://www.immqas.org.uk/downloads/Participation_
Handbook_2018_%202019_(V1).pdf].
TIME KINETICS OF MCT
At the onset of anaphylaxis, tryptase is released from mast cells
alongside other mediators including cytokines, prostaglandin
D2, and leukotriene C4 (3). Compared to histamine MCT has
a longer plasma half-life of ∼2 h (8) (Figure 1). Therefore,
MCT has to date been the main target as a biomarker of
anaphylaxis. Serum MCT concentration rises steeply in the first
90min from the onset of reaction, followed by a steady decline
in concentration following first order kinetics (8). It can take
up to or beyond 24 h for levels to return to pre-reaction or
baseline concentrations.
Serial samples must therefore be tested to demonstrate this
natural progression and aid in the confirmation of anaphylaxis.
The UK National Institute for Health Care Excellence (NICE),
the British Society for Allergy and Clinical Immunology (BSACI)
and the Association of Anesthetists of Great Britain and Ireland
(AAGBI) guidelines recommend serial timed MCT samples–the
first to be taken as soon as possible after emergency treatment has
commenced, a second sample ideally within 1–2 h (but no later
than 4 h) from the onset of symptoms and a baseline sample at
≥24 h (9, 10)1.
INTERPRETATION OF RESULTS
The manufacturer of MCT states a reference range of <11.0
µg/L (95 upper percentile). As with all laboratory tests, the
test performance characteristics [sensitivity, specificity, positive
predictive value (PPV), and negative predictive value (NPV)]
will vary with patient populations due to differences in pre-test
probability and the method of interpretation of data. Previous
studies have reported performance characteristics based on a
peak cut-off of the MCTmeasurement, a percentage change from
baseline or a combination of these (11–13). We reported no
significant difference in these two approaches in the context of
peri-operative anaphylaxis based on area under the curve (14).
Regardless, of the method of interpretation, the key determinant
is to obtain one or more samples during an acute phase and
1http://guidance.nice.org.uk/CG134
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FIGURE 1 | Time kinetics of mast cell tryptase (MCT) during an anaphylactic reaction, from a baseline concentration (pre-reaction), MCT is rapidly released from mast
cells and peaks ∼1–2 h post allergen exposure. T1/2 is ∼2 h. Concentrations return to base line within 24 h after complete resolution of symptoms and signs
of anaphylaxis.
within the half-life (<2 h) alongside a baseline measurement as
described in the previous section. We validated the international
consensus equation (15, 16) on mast cell activation (peak MCT
>1.2 × baseline tryptase + 2 µg/L) in the context of peri-
operative anaphylaxis and showed a high specificity and PPV for
IgE mediated reactions (17).
An ideal laboratory test should have a high (>95%) specificity
and PPV to confirm the condition, and a high (>95%) sensitivity
and high NPV, to exclude and screen for a condition, respectively.
This is difficult to achieve and the threshold is usually set
depending on the purpose of performing the test, the clinical
setting and patient population involved. Altering the cut off
usually has a divergent effect on sensitivity and specificity.
Therefore, increasing the cut-off for an acute MCTmeasurement
or a percentage change in MCT, to enhance specificity will
reduce sensitivity (12–14). Ideally, this should be performed by
the respective laboratories offering the test, based on their local
population and the process can be quite onerous and challenging
for conditions such as anaphylaxis, since a large sample size
will be required alongside controls for constructing receiver
operating characteristic (ROC) curves to generate sensitivity,
specificity, PPV and NPV.
PRACTICAL CONSIDERATIONS RELATING
TO MCT REQUESTS IN
CLINICAL PRACTICE
In specialist allergy practice, a diagnosis of anaphylaxis is based
on clinical criteria as defined by the WAO in conjunction with
an acute MCT, preferably with a baseline measurement (1, 2).
A sample for acute MCT should be obtained within the half-
life (∼2 h) of tryptase. However, a very early sampling time
(<30min), may potentially generate a false negative result since it
may not coincide with a peak rise.Whilst there is no international
consensus regarding a specific time point within this narrow time
window for obtaining an acute sample, the British guidelines1
recommend 2 sampling times (first as soon as possible and
second with 1–2 h but no later than 4 h after onset of symptoms)
to overcome false negative results. It is conceivable that 2 timed
samples as per British guidelines may be challenging to comply
with in a busy emergency department.
Studies undertaken by our group indicate a better uptake of
national guidelines in the context of peri-operative anaphylaxis
than in the emergency room. A recent UK wide National
Audit Project 6 (NAP6) conducted by The Royal College of
Anesthetists found that three timed samples were requested
in 67% of cases, but only 45% met the BSACI guidelines for
“immediate” sampling (<30min) with 76% complying with
sampling within the first hour (18). It is envisaged that the NAP6
has raised awareness amongst UK anesthetists regarding serial
MCT measurements and accurate documentation of signs and
symptoms in all cases of suspected peri-operative anaphylaxis.
We and others have reported that MCT measurements are
not requested in a significant proportion of patients presenting
to the emergency room with anaphylaxis, with compliance as
low as 31–33% in retrospective studies rising only to 69% in a
prospective study (13, 19, 20). Another challenging variable with
respect to MCT measurement is that patients may not arrive in
the emergency room within 2 h from the onset of the reaction,
particularly in cases where symptoms worsen over a few hours
(13, 21). A prospective study by Korosec et al. of patients with
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TABLE 1 | Performance of mast cell tryptase measurement in different clinical settings.
Study Sample
number
Clinical setting Causative agent Number of samples
tested per patient
(time points, hours)
Cut-off Sensitivity Specificity PPV NPV
ACUTE/CONTROLLED SETTING
Brown et al.
(22)
64 Prospective
experimental
Challenge–venom
immunotherapy
Jack jumper ant 3 (Baseline–pre VIT,
0.25, 0.5)
9 µg/L 0.55 0.93 NS NS
12 µg/L 0.36 0.93 NS NS
12 µg/L 0.73 0.98 NS NS
Malinovsky
et al. (12)
31 Prospective Routine
clinical
General anesthesia 3 (0.5, 0.5–1, 24) 12 µg/L 0.64 1.00 1.00 0.53
25 µg/L 0.41 1.00 1.00 0.41
Ratio T0/T24
>3
0.63 0.83 0.92 0.42
Krishna et al.
(14)
161 Retrospective Routine
clinical
General anesthesia 3 (0–1, 1–2, 24) 25 µg/L 0.64 0.74 0.82 0.52
33·6 µg/l 0.53 0.84 0.86 0.49
Percentage
change 506%
0.53 0.84 0.86 0.49
Baretto et al.
(17)
82 Retrospective Routine
clinical
General anesthesia 3 (0–1, 1–2, 24) peak MCT
>1.2xbaseline
tryptase +
2µg/l
0.78 0.91 0.98 0.44
Dua et al. (23) 117 Prospective
experimental Challenge
- food
Peanut 3 (pre-challenge, 0,
1–2)
30% rise from
baseline
0.53 0.85 NS NS
COMMUNITY
Buka et al.
(13)
141 retrospective
emergency
Various 12.4 µg/L 0.28 0.88 0.93 0.17
Korosec et al.
(21)
31 Prospective Emergency venoms (various) 2 (0 and 7/30 days) 11.4 µg/L 0.71 NS NS NS
NS, not stated; PPV, positive predictive value; NPV, negative predictive value.
anaphylaxis presenting to the emergency room, found a median
time to first MCT sample of 1 h 45min, however the range was
1–31 h (21).
The poor rate of MCT requests from the emergency room
may at least in part relate to the busy clinical environment
with priority given to stabilizing the patient and lack of
awareness amongst clinicians regarding MCT measurements.
Also, the sampling time depends on the time taken by the
patient to arrive in the emergency department which in turn
may be influenced by the rapidity in the onset of symptoms
and their severity.
Blood samples for MCT may be taken in EDTA, heparin or
plain tubes without an anticoagulant and preferably analyzed
within 5–7 days. MCT is stable in vitro. However, if there is going
to be an anticipated delay in analysis, samples must be frozen
at−20◦C.
CLINICAL
PERFORMANCE–CONTROLLED SETTING
Using manufacturer cut-offs, the specificity of an elevated MCT
in a controlled clinical setting may show variations (Table 1). In
a study involving insect sting challenges, Brown et al reported
a relatively high specificity of 89% to 93% at a cut-off of 12
µg/L but sensitivity was poor (36%). However, ROC analysis
found an optimal cut-off at 9 µg/L improved sensitivity to
55% with a marginal decline in specificity (87%) (22). This
study however, involved a very small sample size. At a cut-off
of 12 µg/L, Malinovsky et al. reported equal specificity in a
prospective study in the setting of peri-operative anaphylaxis,
but superior sensitivity (64%) (12). Similarly, Mertes et al. in
the context of peri-operative anaphylaxis reported a sensitivity
and specificity of 64 and 89%, respectively for a peak MCT of
>25 mcg/l (11). In a similar setting, we reported a sensitivity
and specificity of 64 and 74%, respectively at a peak MCT
of>25 mcg/l (14).
Alternative methods of interpretations include a change
in MCT concentration from baseline or “delta tryptase”
(peak minus baseline) concentration may be more
discriminatory than peak MCT alone. ROC analysis may
determine a cut-off for optimal delta tryptase to improve
the interpretation. For example, an increase in MCT of
2 µg/L in the study by Brown et al found a sensitivity
of 0.73 (95% CI 0.39–0.94) and specificity 0.91 (95% CI
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0.79–0.97), a superior performance to peak MCT alone
(22). However, we were unable to demonstrate a significant
advantage for a percentage change from baseline vs. absolute
peak MCT measurement in the context of peri-operative
anaphylaxis (14).
The relationship between peak and baseline MCT may also be
expressed as a ratio between peak and baseline or between specific
time point concentrations. For example, Malinovsky determined
T0:T24 concentrations >3 µg/L as the discriminator. However,
this was not found to be as good as increasing the cut-off of
absolute MCT to 25 µg/L (12). As stated in the previous section,
an international consensus equation has been recommended for
the interpretation of mast cell activation (15, 16).
CLINICAL PERFORMANCE OF MCT IN
ANAPHYLAXIS PRESENTING TO THE
EMERGENCY ROOM
There are limited data available regarding the performance of
MCT in an emergency room setting. Differences in performance
of MCT amongst published studies may be attributable to
multiple factors including definition of anaphylaxis employed
(WAO diagnostic criteria were published in 2011), sample size,
assays used for MCT measurement, sampling time, and etiology,
and severity of anaphylaxis. We reported a sensitivity, specificity,
PPV, and NPV of 28%, 88%, 0.93, and 0.17, respectively at a
peak MCT of 12.4 µg/L (13). Practical considerations that are
relevant to this setting also include awareness of the emergency
room physicians regarding the role for MCT in anaphylaxis.
Furthermore, a significant proportion of patients are discharged
from the emergency room after a few hours following recovery,
and may present to an allergy specialist at a different hospital or
organization, and it may be challenging to coordinate the reports
of acute MCT with a baseline measurement.
PERFORMANCE VARIATION WITH
CULPRIT ALLERGEN
Regardless of the clinical setting, it is well-recognized that MCT
may not differ from baseline levels in a significant number of
cases of anaphylaxis (13, 14, 20, 24–26). This statement has
to be cautiously interpreted since some of these studies were
published prior to the publication of theWAO diagnostic criteria
for anaphylaxis. Whilst, it is highly unlikely that this would
have affected cases of severe anaphylaxis as graded by Brown
et al. (27), some cases of mild-moderate anaphylaxis may not
have made their way into the dataset in studies published before
2011, thus potentially affecting the performance characteristics of
MCT. MCT levels have been shown to correlate with histamine.
Furthermore, concurrent lack of elevation in MCT in some
patients with a raised histamine highlights basophil involvement
in anaphylaxis (26). Both histamine and MCT have been shown
to correlate moderately with cutaneous symptoms of erythema
and urticaria in anaphylaxis (26). There is some evidence that
severity of anaphylaxis correlates with serumMCT and histamine
(24, 25), with higher odds (13) for cases with hypotension likely
to be associated with a raised MCT. These data have to be
carefully interpreted since there was no standardization with
respect to interpretation of MCT in anaphylaxis, i.e., cut offs
for an absolute measurement or a percentage change. Although,
it has been suggested that food-induced anaphylaxis is less
likely to be associated with an increased MCT, we and others
reported to the contrary (13, 19). In a recent study of double-
blind-placebo controlled study involving peanut challenges, it
was shown that at least a 30% rise in MCT was seen in 62.5%
of cases (n = 150), out of which 9% developed anaphylaxis,
giving a sensitivity and specificity of 53 and 85%, respectively
(23). It is plausible, however, that the frequency and magnitude
of elevation in MCT may be relatively lower in food-induced
anaphylaxis as opposed to severe cardiovascular anaphylaxis
seen in peri-operative setting (20) (Figure 2). This needs further
investigation in prospective studies where the diagnostic criteria
for anaphylaxis and methods of interpreting MCT are well-
standardized (i.e., apply international consensus equation for
mast cell activation (15, 16).
THE CLINICAL RELEVANCE OF A RAISED
BASELINE MCT
There has been a great clinical interest in baseline MCT in
the context of patients with a previous history of anaphylaxis.
It has been suggested that a constitutively elevated baseline
MCT (≥11.4 µg/L) significantly enhances the risk of severe
anaphylaxis, as seen in patients with hymenoptera venom allergy
(HVA) (28, 29). A cut off 20 µg/L constitutes one of four
minorWHO criteria (30) for systemic mastocytosis, thus making
it an important consideration for a referral for bone marrow
studies. One large study in the context of HVA showed that
the odds of severe anaphylaxis increases 5-fold between 5 and
15 µg/L of baseline MCT (31). Hence, the BSACI criteria for
investigation and management of HVA emphasize on a baseline
MCT measurement in all cases of systemic reactions to insect
stings (32). A raised baseline MCT can also be seen in the context
of chronic renal failure (33, 34) and hematological disorders (35)
such as myelodysplastic syndrome, acute and chronic myeloid
leukemia and chronic eosinophilic leukemia, and hence has to
be carefully interpreted with relevant investigations for renal
function, hematinics, and a clinical examination for mastocytosis
and hematological malignancy. Furthermore, it has also been
shown that 20% of the population may have an elevated
baseline MCT due to hereditary alpha-tryptasaemia (autosomal
dominant) due to increased germline copies of the alpha-tryptase
gene (TPSAB1) (36). These patients have an elevated baseline
MCT with or without non-specific multisystem symptoms. This
has not yet been well-characterized.
USE OF SERUM MCT IN
FORENSIC MEDICINE
A post mortem differential diagnosis of anaphylaxis can be a
challenging task for a histopathologist. Whilst the diagnosis can
be specifically investigated in suspected cases of anaphylaxis,
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FIGURE 2 | Forest plot showing median and interquartile ranges of acute MCT concentrations based on studies with different causative agents/settings of
anaphylaxis. Corresponding table details the publication with 1st author, year, and reference; allergen inducing anaphylaxis, and MCT sampling time was taken for
analysis. Note studies are limited to those where such data was presented. PM, post mortem; NS, not stated.
it is also an important differential diagnosis of sudden
death. The diagnosis is made considering a combination of
variables including circumstances surrounding the death in
conjunction with documented clinical findings by healthcare
professionals, macroscopic features at necropsy (37) (cutaneous
erythema/oedema, upper airway oedema, petechial hemorrhages,
pulmonary congestion/oedema, mucus plugging of bronchi, and
hyperinflation) and post mortem serum MCT measurements.
Data regarding utility of post mortem MCT largely come from
case studies and case series, the latter hampered by relatively
small sample sizes. There are multiple variables that increase the
uncertainty of measurement when serum samples are obtained
from cadavers (38). These have to be carefully factored into the
process of interpretation. Samples must be taken from femoral
vein, and if not the source should be stated with the request to
aid interpretation (38). Also, the method of sample acquisition
should be noted, as femoral vein cut down could result in a
slightly elevated level in comparison to aspiration with a needle
and syringe (39). During autopsy procedures it may be easier to
obtain blood samples from other locations. Cardiac chambers
are known to have higher concentration of MCT compared to
venous blood (38). This is likely to be due to passive diffusion
of MCT post mortem from the relatively larger concentration of
mast cells in the heart and lung. This may also be exacerbated
by prolonged defibrillation or cardiac massage and sudden
cardiovascular fatalities can also give rise to a raised MCT (38).
Hemolysis occurs rapidly post mortem. High hemolysis affects
most enzyme immunoassays (40) and in the case of MCT may
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cause falsely elevated results. Hemolysis may also indicate cell
autolysis or tissue or blood vessel liquefaction. Cell lysis may
cause increased MCT release. Hemodilution (caused from high
fluid volumes ante-mortem) could also affect results causing
false negative results, particularly if samples are taken from a
central line. Therefore, post mortem samples must be taken from
femoral veins.
A high post mortem MCT has also been reported in the
absence of anaphylaxis. Asphyxia can contribute to a high MCT
from femoral blood due to release from lung derived mast cells.
Sudden infant death syndrome (SIDS) has also been associated
with high MCT concentrations, although evidence regarding
this is conflicting and the biological plausibility is unclear and
there are no data on a direct cause-effect relationship (41–44).
Deaths occurring from multiple trauma may have high MCT
levels post mortem as opposed to deaths from single trauma or
“non-trauma” deaths (45). Acute death after heroin injections
has also been implicated in causing increased post mortem
MCT. The time delay between death and sample acquisition
can also affect post mortem MCT concentration. In a recent
post mortem interval study by Woydt et al. (46), statistically
significant differences were seen between paired samples at death
and 3 h post mortem in a cohort where death was not due to
anaphylaxis. One of the 20 cases breached the 44.3 µg/L cut
off at 3 h. However, variation in MCT concentrations with post
mortem intervals has inconsistent evidence.
Given the confounding factors discussed above and
limitations of data, there is no standardized international
reference range for post mortem MCT. Cut-off values proposed
for forensic identification of fatal anaphylaxis vary between
10 and 54 µg/L (39, 47–49). It is worth noting that older
publications (37) (prior to late 1990s) used β MCT as opposed
to total (α and β) MCT in the last decade. Sun et al. recently
published a systematic review and meta-analysis to address this
question and concluded that at concentrations >30.4 µg/L,
sensitivity and specificity for anaphylaxis were 68.5 and 83.9%,
respectively (50).
At the present time, it is not a standard practice to obtain bone
marrow samples during an autopsy. Given that fatal anaphylaxis
is fortunately rare, this may be considered at least in cases where
severe cardiovascular and/or refractory anaphylaxis has occurred
since clonal mast cell disorders have been reported in such
patients (51).
NOVEL BIOMARKERS IN ANAPHYLAXIS
The recent identification of novel biomarkers that are either
released from, or expressed on the surface of activated mast cells,
eosinophils, and basophils have been aided by advances in cell
purification, flow cytometry, and other laboratory techniques.
There is growing evidence to support the investigation
of other biomarkers, such as chymase, carboxypeptidase
A3, dipeptidyl peptidase I (DPPI), basogranulin, CCL-2,
and platelet activating factor (PAF) in the diagnosis of
anaphylaxis. These are described below and summarised
in Table 2.
CHYMASE
In a similar fashion to tryptase, this serine protease is also
largely found in the secretory granules of mast cells. One of
the earliest reports of chymase as a potential biomarker for
anaphylaxis examined 8 autopsy cases with anaphylaxis and
104 control cases without (52). Chymase was detected in all 8
autopsy cases with anaphylaxis, whilst it was only detected in
2 of the 104 control cases. This study also found a significant
positive correlation between chymase and MCT levels in all 8
cases of fatal anaphylaxis. The authors also determined chymase
to be relatively stable in serum, confirming its potential as a
tool in the diagnosis of anaphylaxis. The same group more
recently discovered positive chymase staining in lung mast cells
from 3 autopsy cases of fatal anaphylaxis, in comparison to
the control group of tissues associated with acute traumatic
deaths (53).
Another study (54) established an enzyme immunoassay
(EIA) to examine serum from patients with anaphylaxis
provoked by food, drug and insect stings (n= 181), compared to
a control group of healthy blood donors (n = 123) and patients
with known allergies to food (n = 76) or drugs (n = 26). The
authors found chymase levels to be greater in serum collected
from patients within 8 h of anaphylaxis, compared to the control
group (p = 0.0069). Furthermore, the concentration of chymase
remained high at least 24 h after the onset of the reaction.
CARBOXYPEPTIDASE A3
Alongside MCT and chymase, carboxypeptidase A3 is another
pre-formed chemical mediator of anaphylaxis released by
activated mast cells.
Brown et al (55) measured carboxypeptidase A3 levels by EIA
from blood and saliva, in patients undergoing allergy tests for
suspected drug allergies (n = 33). The found carboxypeptidase
A3 levels to be increased in saliva, but not serum, following
a positive reaction to a drug challenge. Furthermore, baseline
levels of carboxypeptidase A3 were higher in serum and saliva
in patients who experienced symptoms on a drug challenge,
compared to those who were asymptomatic. Baseline levels
were also higher in patients who had historically suffered
a severe reaction including cardiovascular and/or respiratory
compromise, compared to those with only mild reactions.
Another study (56) also used a sandwich-based EIA to
measure levels of carboxypeptidase A3 in cases of suspected
anaphylaxis (n = 181), systemic mastocytosis (30), and control
groups of healthy blood donors (n = 209), or individuals
with bronchial asthma (n = 15). The authors found that
carboxypeptidase A3 levels were significantly greater in the
serum or plasma collected within 8 h of an onset of allergic
reaction, compared to the control cohort. They also found
carboxypeptidase A3 levels to be elevated (although range not
stated) in 83% of anaphylaxis cases with an elevated MCT.
Furthermore, carboxypeptidase A3 was also elevated in 70%
of the 110 cases of suspected anaphylaxis cases that were
MCT negative.
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TABLE 2 | Summary of existing and new biomarkers in anaphylaxis, their (potential) limitations, strengths, and pharmacokinetics.
Biomarker (Potential) limitations (Potential) strengths Pharmacokinetics
Mast cell tryptase (MCT) Variable sensitivity influenced by
clinical setting, timing of sample and
set “cut offs”
Stable in serum, high specificity for
type 1 hypersensitivity reactions
(HSRs)
Half -life approximately 2 h
Histamine (8, 24, 25) Short half-life, poor stability in serum
ex vivo, Serum needs to be frozen
promptly
High specificity for type 1 HSRs,
concentration may correlate with
reaction severity
<15 min
N-methyl histamine* Measured in urine; may be increased
in a variety of non-allergic conditions,
and with bacterial contamination of
urine sample. May be onerous for the
patient as it involves 24 h collection.
Highly correlated with histamine in
plasma
Methylhistamine is a stable end
product of histamine
Chymase (52–54) Limited data to verify Predominantly found in mast cells,
potentially stable in serum
Unknown half-life
Carboxypeptidase A3
(55, 56)
Limited data to verify. Potentially detectable in serum and
saliva; limited data suggests a rise in
anaphylaxis where MCT is not
elevated
Half-life longer than tryptase and this
may potentially be an advantage if
sampling time >2 h from onset of
symptoms. Needs further research
CCL2 (21, 57) Limited data to verify, Basophilic
chemotactic factor
Uncertain, only preliminary data
published. Serum levels may
potentially correlate with the severity
of anaphylaxis
Glycosylation influences its
chemotactic potency and half-life in
vivo
Dipeptidyl Peptidase I
(DPPI) (54, 58)
Non-specific biomarker– expressed in
many other cells
Uncertain, only preliminary data
published
Unknown half-life
Basogranulin (59) Limited data to verify Uncertain, only preliminary data
published. Unique secretory marker
of basophils
Thought to have similar kinetics to
histamine. Levels shown to be
maximal at 15min following
stimulation with anti-IgE antibody
Platelet Activation Factor
(PAF) (25, 60)
Short half-life and special sample
requirements
PAF raised in anaphylaxis Half-life <5 min
Limited utility data is available for some; it is plausible that measurement of combined biomarkers will improve their diagnostic utility.
*https://www.immqas.org.uk/pru.asp?ID=316.
CCL-2
In addition to mast cell mediators being used as biomarkers for
anaphylaxis, there are promising data regarding major basophil
chemotactic factor, chemokine (C-C motif) ligand 2, or CCL-
2. Early studies have demonstrated an influx of basophils to
inflammatory sites within several hours of allergen exposure, thus
confirming a mechanism by which these cells might be recruited
from circulation to the site of allergen exposure (61–63).
The potential use of CCL-2 as a biomarker in anaphylaxis
was examined by one group (21), who measured CCL-2 at 3
time points (during the anaphylactic episode and in convalescent
samples 7 and 30 days later) in 31 patients presenting to the
emergency department with anaphylaxis. The authors found that
the absolute numbers of circulating basophils were significantly
lower during reactions, compared with both the samples taken
in convalescence and in a healthy control cohort. The study
also found the concentration of CCL-2 to be significantly
higher in anaphylaxis, compared to both the samples taken in
convalescence and in the healthy control cohort. They measured
CCL-2 levels in a selection of peanut allergy patients undergoing
a double-blind placebo-controlled peanut challenge. The results
showed CCL-2 levels increased significantly at the time of
objective symptoms, compared with baseline. Furthermore, the
rate of CCL-2 increase was significantly greater in the active
food challenge group compared to the placebo control. The
concentration of CCL-2 was also noted to return to baseline
within 2 h of symptom onset. The authors concluded that at a
cut-off level>334 pg/µL, the estimated sensitivity and specificity
for CCL-2 measurements were 94 and 96%, respectively.
In another more recent study (57), CCL-2 was measured in
serial serum samples from 60 patients with differing severity of
systemic allergic reaction (Mueller grades I–IV) and compared
to 98 healthy controls. The study found CCL-2 levels to be
significantly higher in the patient group, compared to the
healthy control cohort. The authors reported CCL-2 levels to be
significantly higher in acute serum samples from patients with
grade III and IV severity reactions, than in those patients with
systemic grade I reaction. Using paired baseline measurements of
CCL-2, they also showed a significantly higher increase of CCL-
2 in patients with grade IV anaphylaxis compared to those with
grade I reaction. This study not only highlights the use of CCL-2
as a biomarker for anaphylaxis, but also suggests CCL-2 levels in
acute serum correlate with the severity of the reaction.
DIPEPTIDYL PEPTIDASE I (DPPI)
DPP1, also known as Cathepsin C is a member of the papain
family of proteases and is expressed by numerous cell types
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including both mast cells and basophils. Studies using DPP1
knockout mice have proposed a role in activation of chymase, but
not tryptase (58). This is supported by investigation of DPP1 as a
useful serummarker of anaphylaxis (54), where elevated chymase
concentrations in patients with anaphylaxis also correlated with
levels of DPP1, but not tryptase.
BASOGRANULIN
The novel basophil granule protein, termed “basogranulin” has
been shown to be released by basophils in parallel with histamine
and is thought to be dependent on the same receptors and
signaling pathways as those for histamine release (59). Further
work is needed to assess the extent and role of basophil activation
in anaphylaxis and whether basogranulin could be used as a
suitable serum marker.
PLATELET ACTIVATION FACTOR (PAF)
There has been an interest in measuring PAF and PAF
acetylhydrolase (PAF AH), an enzyme inactivating PAF. Platelet
activation factor is a proinflammatory phospholipid secreted
by mast cells, monocytes, and tissue macrophages (25). PAF
binds to its receptors on platelets, monocytes, macrophages,
and neutrophils. Vadas et al. (60) reported an elevated PAF
concentration in anaphylaxis which correlated with severity.
There was an inverse correlation between PAF and PAF AH
activity. They also measured PAF AH activity in patients
with fatal anaphylaxis in peanut allergy and compared it with
controls–PAF AH was significantly reduced in fatal anaphylaxis
samples. In another study, Vadas et al. showed that PAF
correlated better than MCT and histamine with severity of
anaphylaxis (25). One of the challenges withmeasurement of PAF
and PAF AH in a routine clinical setting is its very short half-life
and special sampling and transport precautions that are required
thus making it an unattractive candidate for routine use.
FUTURE PERSPECTIVES
AND CONCLUSIONS
Anaphylaxis remains a clinical diagnosis and biomarkers
have no role in acute management. However, they have an
important place during specialist allergy evaluation to confirm
the diagnosis and distinguish anaphylaxis from its mimics such
as severe asthma, vocal cord dysfunction, factitious disorder or
somatoform disorders, hypotensive crisis due to non-allergic
causes and in certain circumstances where there might be
a paucity of information relating to the index episode. At
the present time, the gold standard laboratory test is MCT,
although other biomarkers such as chymase, carboxypeptidase
A3, and CCL-2 hold promise for the future, providing sample
requirements, assay platform, process, and costs are compatible
for routine use in clinical diagnostic laboratories. Prospective
well-designed multicenter studies applying the WAO diagnostic
criteria for anaphylaxis on well-characterized patients with serial
timed blood samples and standardized methods of interpretation
of serumMCT are needed to firmup on the sensitivity, specificity,
PPV and NPV. There may be a role for a combination of
MCT and a newer biomarker/s to enhance sensitivity and
specificity. Multiplex approach may improve efficiency in a high
throughput diagnostic laboratory using a relatively small amount
of serum. Validation of biomarkers in saliva might be useful
in the interpretation of food challenges, particularly those with
subjective symptoms and minimal or no objective signs.
One of the most intriguing aspects of human anaphylaxis
is that some patients with severe symptoms do not show an
elevated MCT. This raises the possible involvement of other
hitherto unidentified biomarkers and possibly unidentified
pathways. A new classification system based on phenotypes,
endotypes, and biomarkers has been proposed that might
enable a more robust stratification of patients for appropriate
investigations and selection for desensitization, in particular
those developing adverse reactions to biologics, anti-cancer
drugs and radiocontrast media (64). The systems biology
and proteomics approaches applied on serum obtained
during an acute phase and convalescence may be worth
exploring. Greater understanding of the pathogenesis
underpinning anaphylaxis might pave the way for better
risk stratification of patients, improve diagnostics and create
opportunities to develop novel immune-based treatments such as
venom immunotherapy.
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